LIVE
BREAKING LIVE

The news moving markets, right now

From international newswires in real time. For every story the News Impact AI agent estimates the market impact and flags the assets to watch, with the story’s impact on each: positive, negative or neutral.

STORIES TODAY
751
via reuters.comBusiness & Companies

Celldex ends eczema drug development after mid-stage trial failure

FROM THE WIRE · REUTERS.COM

Celldex Therapeutics said on Thursday it would stop developing its experimental drug ​for eczema after the treatment failed to ‌meet the main and key secondary goals of a mid-stage study.

Read at the source ↗
MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralAbandoning a drug in development affects the outlook for the company's pipeline.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
  1. 01Celldex Therapeutics will stop developing its experimental eczema drug.
  2. 02The treatment failed to meet the main and key secondary goals of a mid-stage study.
  3. 03The decision was announced on Thursday.

ALL BREAKING TODAY

Breaking live stories come from third-party newswires via feed; headline and summary belong to the stated source. Impact analysis: UCapital AI · News Impact.

AI use policy. UCapital AI supports the newsroom with news analysis, summaries, market reactions, translations and the generation of cards and charts. AI-generated or AI-assisted content is labelled in the byline (AI Desk, a named AI profile marked «AI», or joint byline) and is reviewed by editors before publication. News received via API feeds from third-party providers is attributed to the original source. AI can make mistakes: report any inaccuracies to the newsroom. Users’ personal data is not used to train the models.